Renatus Tactical Acquisition is a Cayman blank-check still sitting in the search phase more than a year after an upsized offering, and the investment case is no longer about whether the trust is funded. The vehicle has a fully accreted cash account and a public common that trades essentially at that cash. What has changed is the operating shell around the account. Outside cash has collapsed to a rounding error, management has flagged substantial doubt about continuing as a going concern, and no target has been named. The debate is whether the remaining combination window still prices any real option, or whether the market is simply warehousing cash until a deal appears or the clock expires.
The summer board episode makes that tension concrete. An independent director resigned in early June, the company told Nasdaq it had fallen out of the three-member audit-committee rule and the majority-independent board rule, and it invoked the listing-rule cure periods. Lauren Selig joined the board and the three committees in late July, restoring the committee math without a cash stipend. The sponsor is transferring a block of founder shares instead. That repair removes a near-term listing snag. It does not refill the operating account or produce a signed combination.
The midyear print showed trust interest still covering the search burn on a reported-income basis, while cash outside the trust fell to $477. Convertible working-capital draws from the sponsor and other noteholders are now the only practical way the shell pays lawyers and the monthly administrative fee. The common last changed hands just under the midyear redemption value. Does a signed agreement arrive before the May 2027 deadline, or does the vehicle spend the next several quarters as a cash warehouse with a thinning operating cushion?